A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)
- Neurodegenerative Disorder
The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.
The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.
This is a Phase IV, prospective, multi-center, open-label study to assess the effectiveness and safety profile of epoetin beta (Recormon®) for treatment of symptomatic anemia in adult participants associated with low/intermediate-1-risk MDS. After screening, eligible participants will be treated with epoetin beta as recommended in the approved label and international guidelines for the use of epoetin in MDS participants and the dosage will be adjusted on the basis of erythroid response.
A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)
- Adult participants with low or intermediate-1 risk MDS
- No previous treatment with hematopoietic growth factors within 3 months prior to screening
- Symptomatic anemia (hemoglobin <10 g/dL) as determined by investigator
- Serum erythropoietin <500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment
- Require no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening
- Clinically stable for at least 1 month prior to entry into the study
- For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception
- Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment
- Poorly controlled hypertension as assessed by the investigator
- History of Acute Myeloid Leukemia (AML) or high risk for AML
- Administration of another investigational drug within 1 month before screening or planned during the study period
- Previously documented evidence of Pure Red Cell Aplasia (PRCA)
For the latest version of this information please go to www.forpatients.roche.com